Dante Antonelli MD, Yoav Turgeman MD, Rafael Wolff MD, Avi Sebanciev MD, Meir Tabi MD
Surgical aortic valve replacement (SAVR) is the treatment of choice for patients with severe aortic stenosis (sAS). Balloon aortic valvuloplasty (BAV) was developed 40 years ago, and it was an alternative to conventional SAVR in elderly and frail patients for whom there were no other effective therapeutic options [1].
Transcatheter aortic valve intervention (TAVI) has expanded its indications during the last 20 years, from prohibitively high surgical risk of mortality to intermediate risk patients [2].
We reported a case of BAV that was used as a bridge to TAVI in an elderly patient with sAS, congestive heart failure (CHF), and ischemic hepatitis (IH).